LGVN
LGVN
NASDAQ · Biotechnology

Longeveron Inc-A

$1.09
+0.05 (+4.81%)
Financial Highlights (FY 2026)
Revenue
5.87M
Net Income
-39,203,929
Gross Margin
78.8%
Profit Margin
-667.8%
Rev Growth
+22.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 78.8% 78.8% 43.6% 43.6%
Operating Margin -690.7% -621.6% -2.2% -2.6%
Profit Margin -667.8% -634.4% -2.4% -2.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.87M 4.80M 3.54M 3.93M
Gross Profit 4.62M 3.78M 1.54M 1.71M
Operating Income -40,557,772 -29,834,078 -77,362 -100,425
Net Income -39,203,929 -28,838,198 -86,327 -108,943
Gross Margin 78.8% 78.8% 43.6% 43.6%
Operating Margin -690.7% -621.6% -2.2% -2.6%
Profit Margin -667.8% -634.4% -2.4% -2.8%
Rev Growth +22.4% +22.4% +8.8% +5.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 4.00M 4.40M
Total Equity 6.27M 5.45M
D/E Ratio 0.64 0.81
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -36,850,122 -28,612,681 -134,724 -147,370
Free Cash Flow -61,141 -91,187